Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Tislelizumab is now approved for seven indications in China
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Subscribe To Our Newsletter & Stay Updated
